- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01007422
Opioids Titration in Hospice Patients
Opioid Titration In the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and Protocol Stage 2, Part B
RATIONALE: Opioids lessen pain caused by cancer. Titration of opioids in the hospice setting is suboptimal due to numerous barriers. Order sets may help to provide timely and effective medical and pharmaceutical intervention.
PURPOSE: The purpose of this study was to identify barriers to good pain control in the hospice setting and to develop an order set that would safely address these barriers.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
- Annen: medisinsk kartgjennomgang
- Annen: undersøkelsesadministrasjon
- Fremgangsmåte: psykososial vurdering og omsorg
- Atferdsmessig: telefonbasert intervensjon
- Fremgangsmåte: smertebehandling
- Fremgangsmåte: behandling/behandling ved livets slutt
- Annen: kommunikasjonsintervensjon
- Annen: intervention by caregiver
Detaljert beskrivelse
Objective 1:
To assess barriers to pain control in the hospice setting.
Using a mixed methods approach, key stakeholders including physicians, nurses, patients and caregivers were queried about pain control in the hospice setting, barriers to pain control and the desirability of an order set to address this issue.
Objective 2:
To develop and conduct pilot testing of an order set designed to improve pain control in the hospice setting.
An opioid titration order sheet based on our previous R0-1 was modified based on the information derived from the interviews and questionnaires completed by the physicians, nurses, patients and caregivers.
A cohort of 20 patients were enrolled on the first phase of the pilot study in order to test the modified pain assessment form and the feasibility administration of the study materials to be completed by the patient and caregiver. Forms are as follows:
- Patient assessment: At baseline, patients provide demographic data and complete the Pain Assessment Form and the Pain Communication Survey. The pain assessment form addresses average pain, worst pain, pain relief, hours in pain, pain-related distress, and barriers to pain control. Patients are asked to rate pain control. Patients also complete the Pain Communication Survey to assess how they communicate with healthcare providers about their pain. After the baseline assessment is completed, patients complete the Pain Assessment form on a daily basis. Pain is also assessed by the research nurse at least 3 times weekly (1 home visit* and 2 telephone interviews). Patients are followed until the time of death.
NOTE: *If a patient is hospitalized or transferred to the inpatient hospice facility, the patient interview will take place there.
- Caregiver assessment: At baseline, caregivers complete a demographic survey, a Pain Assessment Form, the Pain Communication Survey, Caregiver Self-Efficacy in Pain Management Scale (CSEPMS), Caregiver Pain Management Questionnaire (CPMQ), and the Stressful Caregiver Adult Reactions to Experiences of Dying (SCARED). Caregivers are then interviewed by the study nurse using the Pain Assessment Form as a guideline to obtain more detailed information about adequacy of the patient's pain control, side effects of medication, barriers to pain control, and caregiver concerns and burden. Follow-up data from caregivers is obtained through completion of CSEPMS, CPMQ, and SCARED questionnaires and their assessment of patient's pain form at the end of weeks 1, 2, and 3.
- Chart review: A research nurse conducts a chart review after patient's death. Cancer and cancer-related treatment data is obtained and documentation about pain management is recorded. From the time of study entry, all staff notes are reviewed to document pain assessment, calls to physician or other support personnel (including pharmacy calls), identified barriers to pain control, and treatment modifications (including medications to treat side effects).
After 20 patients, it was deemed not feasible to complete the study forms and to recruit adequately for the trial. The study was suspended.
Studietype
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
DISEASE CHARACTERISTICS:
Meets 1 of the following criteria:
Outpatient at the Alive Hospice in the State of Tennessee
- Diagnosed with carcinoma
- Pain requiring fixed-dose opioids
Caregiver for an Alive Hospice patient
- Any caregiver who is identified by the patient is eligible
PATIENT CHARACTERISTICS:
- Not pregnant or nursing
- Able to speak/comprehend English
- Lives within a 60-mile radius of Alive Hospice
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
Supportive Care
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
To obtain determine the safety and feasibility of an opioid titration order sheet in the hospice setting.
Tidsramme: at 4 weeks
|
Pain assessments will be completed at baseline and daily for 4 weeks.
Survey instruments will be completed at the end of weeks 1, 2, and 3.
|
at 4 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Barbara A. Murphy, MD, Vanderbilt-Ingram Cancer Center
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- VICC SUPP 0822
- P30CA068485 (U.S. NIH-stipend/kontrakt)
- VU-VICC-SUPP-0822
- VU-VICC-IRB-IRB-080370
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Smerte
-
East Carolina UniversityTilbaketrukket
-
Wake Forest University Health SciencesRekruttering
-
Cairo UniversityFullførtCervical Myofascial Pain SyndromeEgypt
-
Dilşad SindelFullførtKvinnelige pasienter med Myofascial Pain Syndrome (MPS) relatert til øvre Trapezius Active Trigger Points (TP)
-
Brugmann University HospitalTilbaketrukketPhantom Limb Pain (PLP) | Primær/sekundær arrhyperalgesiBelgia
-
Oslo University HospitalUniversity of Oslo; Fysiofondet; Oslo Metropolitan UniversityRekrutteringGluteal tendinopati | Trochanterisk bursitt | Lateral hoftesmerter | GTPS - Greater Trochanteric Pain SyndromeNorge
-
University of JazanRekrutteringOvervekt | Kroppsvekt | Smarttelefonavhengighet | Cervical Myofascial Pain SyndromeSaudi-Arabia
-
Mustafa Kemal UniversityRekrutteringEffekten av Dextrose Prolotherapy i Myofascial Pain SyndromeTyrkia
-
University Hospitals, LeicesterFullførtMagesmerter | Abdominal Myofascial Pain Syndrome (AMPS) | Abdominal Plane Blocks (APB)Storbritannia
-
Yuzuncu Yıl UniversityFullførtMyofascial Pain Dysfunction Syndrome, Temporomandibulært leddTyrkia
Kliniske studier på medisinsk kartgjennomgang
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Avsluttet
-
M.D. Anderson Cancer CenterRekrutteringHematopoetisk og lymfoid celle-neoplasma | Ondartet fast neoplasmaForente stater
-
Mayo ClinicNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeOndartet neoplasma i sentralnervesystemet | Ondartet skull base neoplasmaForente stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekrutteringHematopoetisk og lymfoid celle-neoplasma | Ondartet fast neoplasmaForente stater
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of Arkansas; The Emmes Company...FullførtForekomst og forekomst av kreft hos mennesker som lever med HIV/AIDS ved kreftsentre i Latin-AmerikaHIV-infeksjon | Ondartet neoplasma | Tilbakevendende ondartet neoplasma | Humant immunsviktvirus 1 positivMexico, Argentina, Brasil
-
M.D. Anderson Cancer CenterRekrutteringKutant melanomForente stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeHode- og nakkekarsinomForente stater
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)FullførtTilbakevendende uterin Corpus Sarkom | Tilbakevendende livmorkarsinom | Stadium I Livmor Corpus Cancer | Stadium II Livmor Corpus Cancer | Stadium III Livmor Corpus Cancer | Stadium IV Livmor Corpus Cancer | Tilbakevendende livmorhalskreft | Stadium III livmorsarkom | Stadium IV livmorsarkom | Stadium I livmorsarkom og andre forholdForente stater
-
M.D. Anderson Cancer CenterNational Institute of Allergy and Infectious Diseases (NIAID)RekrutteringBronchiolitis ObliteransForente stater
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of California, San Diego; University...AvsluttetAIDS-relatert primært effusjonslymfomForente stater